Wednesday September 19, 2018

New Biomarker Helps Identify Cancer Chemotherapy Timing

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug's effectiveness

0
//
38
Biomarker can be used to decide timing fro chemotherapy.
Republish
Reprint

In ray of hope for doctors to identify the tumour normalising period for effective timing of anti-cancer drug treatment, a team of researchers have discovered a new biomarker that can visualise the activity of blood vessels.

Angiogenesis, the formation of new blood vessels, is essential for tumour growth. The team from Osaka University in Japan, in a paper reported in The American Journal of Pathology, described a vascular stabilization biomarker that can visualize blood vessel activity, thus optimising the timing of anticancer therapies including anti-angiogenics.

Chronic diseases are not yet included in cancer prevention schemes.
This can help cancer patients greatly.

Combination therapy using angiogenesis inhibitors and anticancer drugs can improve drug delivery into tumour tissues and prolong progression-free survival. “Vascular normalisation by angiogenesis inhibitors, such as vascular endothelial growth factor (VEGF) signaling inhibitors, is a promising method for improvement of chemotherapy.

“However, it is unclear how we can recognise the ‘window of opportunity’ for the tumour vascular normalising period for effective timing of anti-cancer drug treatment. Therefore, biomarkers delineating this window are essential,” explained Nobuyuki Takakura, Professor at Research Institute for Microbial Diseases, Osaka University.

Also Read: What We Know About Cancer Risk and Coffee

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug’s effectiveness. Basic research indicates that anti-angiogenic therapy allows the blood vessels to return to quiescence and “normalise” so that the anti-cancer drug can penetrate the tumour more effectively. IANS

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Gut Microbiota Can Help Identify Liver Cancer: Researchers

Gut microbiota can help the body digest certain foods that the stomach and small intestine have not been able to digest.

0
Liver Cancer
How gut microbiota can aid in early diagnosis of liver cancer.

Chinese researchers have identified gut microbiota as a new biomarker of liver cancer, that can help in early diagnosis as well as treatment of the condition.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related death worldwide.

Due to the absence of specific symptoms in early stages and the lack of diagnostic markers, most patients with HCC are often diagnosed in an advanced stage.

Liver Cancer
AFP is a plasma protein that is produced in abundance by the liver cells. Pixabay

Researchers from China’s Zhejiang University, and Zhengzhou University, found that the microbial diversity in patients with cirrhosis was significantly lower than that in healthy people, but it increased when cirrhosis develops into cancer, the Xinhua reported.

Human gut microbiota has been considered the most important micro-ecosystem living with the body, containing tens of trillions of microorganisms, including at least 1,000 species of bacteria with more than 3 million genes.

Gut microbiota can help the body digest certain foods that the stomach and small intestine have not been able to digest.

Liver Cancer
A high-magnification image from a 2012 glioblastoma case is seen as an example in this College of American Pathologists image released from Northfield. VOA

For the study, appearing in the journal Gut, the team collected 486 fecal samples from across the country.

Also Read: Deaths Due to Cancer Increases to More Than 18 Mn Every Year: WHO

About 12 bacteria genera decreased and six increased in patients with early cancer compared with healthy people.

According to researchers, more data and further studies are needed to confirm the validity and reliability of the model. (IANS)